|
|
 |
|
Viewing report
|
|
|
|
Product Profiles: Asthma/COPD - Novel Combinations Edge Closer to Market
Datamonitor, Oct 2011, Pages: 157
Despite a number of well-established therapies, the asthma/COPD pipeline remains highly active. A number of products have progressed in the pipeline and significant new data have been presented at this year’s respiratory conferences. Numerous product launches are expected in the next 10 years, which will fragment the markets, although a handful of companies will maintain market dominance.
Features and benefits
- Access Datamonitor’s independent clinical and commercial assessment of marketed brands and key pipeline agents for asthma and COPD.
- Understand to what extent current and future therapies satisfy the main clinical unmet needs in asthma and COPD.
- Assess how pipeline products compare to each other and how they will compete with established therapies.
- Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
Highlights
- GlaxoSmithKline dominates the asthma/COPD market with Advair. However, with a number of ICS/LABA combinations now available and generic Advair in development, the brand’s position is coming under threat. To counter this, GlaxoSmithKline is developing once-daily Relovair, which is on track to become the first once-daily ICS/LABA to reach the market.
- Spiriva (Boehringer Ingelheim) is the clear gold-standard monotherapy for COPD, and remains the only LAMA available. Numerous LABA/LAMA combinations are moving through the pipeline, many of which are being directly compared to Spiriva in clinical trials. If approved, these products could offer improved efficacy with simplified treatment.
- A number of companies are believed to be developing generic versions of Advair and Symbicort. Datamonitor believes that extensive clinical trial programs will be required to bring these to market, and that, if approved, they will launch as branded generics, offering a lower price discount than seen for less complex drugs.
Your key questions answered
- How do marketed treatments of asthma/COPD compare to one another and where will pipeline agents fit in?
- How are current respiratory players protecting their market position in the face of increasing competition?
- Which pipeline products will need to compete with currently established treatments, and which will be positioned as add-on therapies?
- How is asthma/COPD treatment expected to change as novel therapies move through the pipeline?
|
|
|
|
